Literature DB >> 11446571

Influenza and pneumococcal vaccination levels among persons aged > or = 65 years--United States, 1999.

.   

Abstract

Annual influenza epidemics have resulted in an average of >18,000 deaths and 48,000 pneumonia and influenza hospitalizations among older persons in the United States (1). In 1998, an estimated 3400 older persons died from bacteremic pneumococcal pneumonia, a common complication of influenza, or from other forms of invasive pneumococcal disease (2 ). A 2000 national health objective included increasing influenza and pneumococcal vaccination levels to > or = 60% among noninstitutionalized, high-risk persons, including those aged > or = 65 years (3). To assess progress toward this objective, data were analyzed from the 1999 Behavioral Risk Factor Surveillance System (BRFSS) for persons aged > or = 65 years. This report summarizes the results of that analysis, which indicated that prevalence of influenza vaccination during the 1998-99 influenza season exceeded the objective nationally and in 48 of 52 reporting areas; however, influenza vaccination levels may have reached a plateau. Prevalence among older persons who had ever received pneumococcal vaccination exceeded the national objective in only eight states. To reach the 2010 national objective of > or = 90% influenza and pneumococcal vaccination among this population, new strategies and additional resources to implement adult vaccination activities may be needed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11446571

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  19 in total

1.  Tailoring interventions: understanding medical practice culture.

Authors:  Myrna Silverman; Martha A Terry; Richard K Zimmerman; Jean F Nutini; Edmund M Ricci
Journal:  J Cross Cult Gerontol       Date:  2004-06

Review 2.  Antiviral agents for influenza: a comparison of cost-effectiveness data.

Authors:  Larry D Lynd; Ron Goeree; Bernie J O'Brien
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Increasing inner-city adult influenza vaccination rates: a randomized controlled trial.

Authors:  Sharon G Humiston; Nancy M Bennett; Christine Long; Shirley Eberly; Lourdes Arvelo; Joseph Stankaitis; Peter G Szilagyi
Journal:  Public Health Rep       Date:  2011 Jul-Aug       Impact factor: 2.792

4.  Effects of mass media coverage on timing and annual receipt of influenza vaccination among Medicare elderly.

Authors:  Byung-Kwang Yoo; Margaret L Holland; Jay Bhattacharya; Charles E Phelps; Peter G Szilagyi
Journal:  Health Serv Res       Date:  2010-10       Impact factor: 3.402

5.  Influenza and pneumonia vaccination rates in patients hospitalized with acute respiratory failure.

Authors:  Ipek Candemir; Sema Turk; Pinar Ergun; Dicle Kaymaz
Journal:  Hum Vaccin Immunother       Date:  2019-06-03       Impact factor: 3.452

Review 6.  Intranasal cold-adapted influenza virus vaccine combined with inactivated influenza virus vaccines: an extra boost for the elderly?

Authors:  Paul V Targonski; Gregory A Poland
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 7.  Myocardial infarction, stroke, and sudden cardiac death may be prevented by influenza vaccination.

Authors:  David G Meyers
Journal:  Curr Atheroscler Rep       Date:  2003-03       Impact factor: 5.113

8.  A national survey of physician practices regarding influenza vaccine.

Authors:  Matthew M Davis; Shawn R McMahon; Jeanne M Santoli; Benjamin Schwartz; Sarah J Clark
Journal:  J Gen Intern Med       Date:  2002-09       Impact factor: 5.128

Review 9.  Pneumococcal vaccination and revaccination of older adults.

Authors:  Andrew S Artz; William B Ershler; Dan L Longo
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

10.  Threat-responsiveness and the decision to obtain free influenza vaccinations among the older adults in Taiwan.

Authors:  Ying-Chun Li; Chi-Mei Liu
Journal:  BMC Public Health       Date:  2009-07-31       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.